CalciMedica Inc. (NASDAQ: CALC) announced the discontinuation of its Phase 2 KOURAGE clinical trial evaluating Auxora in patients with acute ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE